<DOC>
	<DOCNO>NCT02997202</DOCNO>
	<brief_summary>The purpose study compare relapse-free survival participant FLT3/ITD AML first morphologic complete remission ( CR1 ) undergo hematopoietic stem cell transplant ( HCT ) randomize receive gilteritinib placebo begin time engraftment two year period .</brief_summary>
	<brief_title>A Trial FMS-like Tyrosine Kinase 3 ( FLT3 ) Inhibitor Gilteritinib Administered Maintenance Therapy Following Allogeneic Transplant Patients With FLT3/Internal Tandem Duplication ( ITD ) Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Participants FLT3/ITD AML first morphologic complete remission ( CR1 ) undergo allogeneic hematopoietic stem cell transplant ( HCT ) randomize receive gilteritinib placebo 30 90 day HCT two year period . Participants stratify accord : 1 ) condition regimen intensity ( myeloablative vs. reduce intensity ) , 2 ) time HCT randomization ( 30-60 day vs. 61-90 day ) 3 ) presence absence minimal residual disease ( MRD ) recent pre-registration bone marrow ( BM ) aspirate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Registration Inclusion Criteria Participant consider suitable candidate HCT acceptable source allogeneic donor stem cell , define per institutional practice ( allogeneic HCT donor source [ match sibling , unrelated donor ( URD ) , mismatch URD , related haploidentical , umbilical cord blood ] graft source [ umbilical cord , BM , peripheral blood ( PB ) ] , condition [ myeloablative conditioning ( MAC ) , reduce intensity conditioning ( RIC ) , nonmyeloablative conditioning ( NMA ) ] permit ) . Participant consider legal adult local regulation time sign informed consent form ( ICF ) . Participant consent allow access diagnostic BM aspirate PB sample and/or DNA derive sample , available , may use validate companion diagnostic develop parallel gilteritinib . Participant confirm , morphologically document AML CR1 . For purpose registration , CR1 define &lt; 5 % blast BM morphologic characteristic acute leukemia ( e.g. , Auer Rods ) BM evidence extramedullary disease central nervous system involvement granulocytic sarcoma . Participant receive 2 cycle induction chemotherapy achieve CR1 . The induction cycle regimen different regimen . The regimen ( ) may contain conventional agent , investigational agent , combination . Participants CR incomplete count recovery ( CRp CRi ) allow . Incomplete platelet recovery ( CRp ) define CR platelet count &lt; 100 x 109/L . Incomplete hematologic recovery ( CRi ) define CR residual neutropenia &lt; 1 x 109/L without complete platelet recovery . RBC platelet transfusion independence require . The maximum time allow establishment CR1 registration 12 month . Participant presence FLT3/ITD activate mutation BM PB determine local institution diagnosis . Participant must meet follow criterion indicate clinical laboratory test : Serum creatinine within normal range , serum creatinine outside normal range , glomerular filtration rate ( GFR ) &gt; 40 mL/min/1.73m2 calculate CockcroftGault equation adjustment total body weight ≥ 125 % ideal body weight . Total bilirubin ( TBL ) ≤ 2.5 mg/dL , except participant Gilbert 's syndrome . Serum AST and/or alanine aminotransferase ( ALT ) &lt; 3 x institutional upper limit normal ( ULN ) . Serum potassium magnesium great institutional low limit normal ( LLN ) . Participant leave ventricular ejection fraction rest ≥ 40 % . Participant diffuse capacity lung carbon monoxide ( DLCO ) ( correct hemoglobin ) , forced expiratory volume 1 second ( FEV1 ) , force vital capacity ( FVC ) &gt; 50 % predict . Female participant must either : Be nonchildbearing potential : postmenopausal ( define least 1 year without menses ) prior screen document surgically sterilize ( least 1 month prior screen visit ) Or , childbearing potential , Agree try become pregnant study 60 day final study drug administration And negative serum pregnancy test screening And , heterosexually active , agree consistently use highly effective contraception per locally accept standard addition barrier method start screen throughout study period 60 day final study drug administration . Female participant must agree breastfeed donate ovum screen throughout study period 60 day final study drug administration . Male participant ( even surgically sterilize ) , partner woman childbearing potential must use highly effective contraception addition barrier method start screen throughout study period 120 day final study drug administration . Male participant must donate sperm start screen throughout study period 120 day final study drug administration . Participant able take oral medication . Participant agree participate another interventional study treatment . Randomization Inclusion Criteria Participant ≥ 30 day ≤ 90 day stem cell infusion . Participant ANC ≥ 500/μL platelet ≥ 20000/μL absence platelet transfusion within prior 7 day . Participant use investigational agent within prior 4 week . Participant confirm ongoing morphologically document AML CR1 . For purpose randomization , CR1 define &lt; 5 % blast morphologic characteristic acute leukemia ( e.g. , Auer Rods ) BM evidence extramedullary disease central nervous system involvement granulocytic sarcoma . Participant must meet follow criterion indicate clinical laboratory test : Serum creatinine within normal range , serum creatinine outside normal range , GFR &gt; 40 mL/min/1.73m2 calculate CockroftGault equation adjustment total body weight ≥ 125 % ideal body weight . TBL &lt; 2.5 mg/dL , except participant Gilbert 's syndrome . Serum AST and/or ALT &lt; 3 x institutional ULN . Serum potassium magnesium great institutional LLN . Participant need supplemental oxygen exception use previously exist noninvasive continuous positive airway pressure ( CPAP ) night If participant develop overall grade IIIV acute GVHD , follow criterion must meet randomize : No requirement &gt; 0.5 mg/kg prednisone ( equivalent ) daily dose within 1 week randomization No escalation immunosuppression term increase corticosteroid addition new agent / modality prior 2 week ( note increase calcineurin inhibitor sirolimus achieve therapeutic trough level allow ) Participant use experimental therapy acute GVHD prior 4 week . If unsure definition `` experimental '' , discussion one protocol chair encourage . Participant able take oral medication Registration Exclusion Criteria Participant prior allogeneic transplant . Participant Karnofsky performance status score &lt; 70 % . Participant require treatment concomitant drug strong inducer CYP3A4 . Participant require treatment concomitant drug target serotonin 5hydroxytryptamine receptor 1 ( 5HT1R ) 5hydroxytryptamine receptor 2B ( 5HT2BR ) sigma nonspecific receptor exception drug consider absolutely essential care participant . Participant Fridericiacorrected QT interval ( QTcF ) &gt; 450 msec ( average triplicate determination ) . Participant long QT Syndrome screening . Participant known infection human immunodeficiency virus ( HIV ) determine serology nucleic acid amplification test ( NAAT ) . Participant active hepatitis B infection determine NAAT surface antigen assay . Participants acquire immunity past exposure ( HBcAb positive / HBsAb positive / HBsAg negative ) eligible . Participant active hepatitis C infection determine NAAT . Participants past exposure detectable virus either spontaneous clearance treatment eligible . Participant uncontrolled infection exclude . If bacterial viral infection present , participant must receive definitive therapy sign progress infection 72 hour prior registration . If fungal infection present , participant must receive definitive systemic antifungal therapy sign progress infection 1 week prior registration . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . Participant myocardial infarction within 6 month prior registration New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia . Participant serious medical psychiatric illness likely interfere participation clinical study . Female participant breast feed pregnant . Participant prior malignancy , except lobular breast carcinoma situ , fully resect basal cell squamous cell carcinoma skin treat cervical carcinoma situ . Cancer treat curative intent &gt; 5 year previously allow . Cancer treat curative intent &lt; 5 year previously allow . Randomization Exclusion Criteria Participant require treatment concomitant drug strong inducer CYP3A4 . Participant require treatment concomitant drug target serotonin 5HT1R 5HT2BR sigma nonspecific receptor exception drug consider investigator absolutely essential care participant acceptable alternative exists . Participant QTcF interval &gt; 450 msec ( average triplicate determination ) . Participant uncontrolled infection exclude . If bacterial viral infection present , participant must receive definitive therapy sign progress infection 72 hour prior randomization . If fungal infection present , participant must receive definitive systemic antifungal therapy sign progress infection 1 week prior randomization . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gilteritinib</keyword>
	<keyword>ASP2215</keyword>
	<keyword>Safety Efficacy</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
</DOC>